AU2013206890B2 - Methods of treating behavioral symptoms of neurological and mental disorders - Google Patents

Methods of treating behavioral symptoms of neurological and mental disorders Download PDF

Info

Publication number
AU2013206890B2
AU2013206890B2 AU2013206890A AU2013206890A AU2013206890B2 AU 2013206890 B2 AU2013206890 B2 AU 2013206890B2 AU 2013206890 A AU2013206890 A AU 2013206890A AU 2013206890 A AU2013206890 A AU 2013206890A AU 2013206890 B2 AU2013206890 B2 AU 2013206890B2
Authority
AU
Australia
Prior art keywords
subject
medicament
administration
administered
asd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013206890A
Other languages
English (en)
Other versions
AU2013206890A1 (en
Inventor
James J. Fallon
Joan M. Fallon
Matthew F. Heil
Kenneth NANUS
James Szigethy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curemark LLC
Original Assignee
Curemark LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curemark LLC filed Critical Curemark LLC
Publication of AU2013206890A1 publication Critical patent/AU2013206890A1/en
Priority to AU2017232048A priority Critical patent/AU2017232048B2/en
Application granted granted Critical
Publication of AU2013206890B2 publication Critical patent/AU2013206890B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Closures For Containers (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AU2013206890A 2012-01-03 2013-01-03 Methods of treating behavioral symptoms of neurological and mental disorders Active AU2013206890B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017232048A AU2017232048B2 (en) 2012-01-03 2017-09-19 Methods of treating behavioral symptoms of neurological and mental disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261582813P 2012-01-03 2012-01-03
US61/582,813 2012-01-03
US201261600110P 2012-02-17 2012-02-17
US61/600,110 2012-02-17
PCT/US2013/020183 WO2013103746A1 (en) 2012-01-03 2013-01-03 Methods of treating behavioral symptoms of neurological and mental disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017232048A Division AU2017232048B2 (en) 2012-01-03 2017-09-19 Methods of treating behavioral symptoms of neurological and mental disorders

Publications (2)

Publication Number Publication Date
AU2013206890A1 AU2013206890A1 (en) 2014-07-24
AU2013206890B2 true AU2013206890B2 (en) 2017-09-28

Family

ID=48745413

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013206890A Active AU2013206890B2 (en) 2012-01-03 2013-01-03 Methods of treating behavioral symptoms of neurological and mental disorders
AU2017232048A Active AU2017232048B2 (en) 2012-01-03 2017-09-19 Methods of treating behavioral symptoms of neurological and mental disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017232048A Active AU2017232048B2 (en) 2012-01-03 2017-09-19 Methods of treating behavioral symptoms of neurological and mental disorders

Country Status (16)

Country Link
US (3) US20130224172A1 (enExample)
EP (1) EP2800581B1 (enExample)
JP (3) JP6796372B2 (enExample)
KR (3) KR20190109564A (enExample)
CN (2) CN104144698A (enExample)
AU (2) AU2013206890B2 (enExample)
BR (1) BR112014016557A8 (enExample)
CA (1) CA2862403C (enExample)
DK (1) DK2800581T3 (enExample)
GB (1) GB2511713B (enExample)
HK (1) HK1257360A1 (enExample)
IL (1) IL233372B (enExample)
MX (2) MX363096B (enExample)
NZ (2) NZ737957A (enExample)
RU (1) RU2654230C2 (enExample)
WO (1) WO2013103746A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
AU2016247301A1 (en) * 2015-04-14 2017-10-26 Steven Hoffman Compositions and methods for treating autism
CN105213433A (zh) * 2015-11-06 2016-01-06 王益超 一种用于治疗孤独症、复发性流产和不孕症的组合物
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11547707B2 (en) * 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US20210043106A1 (en) * 2019-08-08 2021-02-11 COGNITIVEBOTICS Technologies Pvt. Ltd. Technology based learning platform for persons having autism
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN112347257B (zh) * 2020-11-11 2024-07-09 北京嘉和海森健康科技有限公司 一种患者症状口语化标准化方法和装置
WO2023201358A2 (en) * 2022-04-15 2023-10-19 AEON Biopharma, Inc. Neurotoxin compositions for use in regulating brain temperature

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001575A1 (en) * 2000-05-26 2002-01-03 Foreman David J. Nutritional system for nervous system disorders
US20080112944A1 (en) * 2004-12-01 2008-05-15 Kirkman Group, Inc. Compositions and methods for the treatment of autism
WO2010002972A1 (en) * 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
WO2010120781A1 (en) * 2009-04-13 2010-10-21 Curemark Llc Enzyme delivery systems and methods of preparations and use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6534063B1 (en) * 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
US6251478B1 (en) 1999-12-22 2001-06-26 Balchem Corporation Sensitive substance encapsulation
US6261613B1 (en) 2000-02-15 2001-07-17 General Mills, Inc. Refrigerated and shelf-stable bakery dough products
US6660831B2 (en) 2000-08-14 2003-12-09 Joan M. Fallon Method for diagnosing and treating dysautonomia and other dysautonomic conditions
DE10065123B4 (de) * 2000-12-28 2012-12-20 Robert Bosch Gmbh Verfahren zur Steuerung einer Diagnose eines Katalysators im Abgas eines Verbrennungsmotors
AU2002364750A1 (en) * 2001-12-14 2003-06-30 Solvay Pharmaceuticals Gmbh Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans
CA2560613C (en) * 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
JP5914357B2 (ja) * 2010-01-15 2016-05-11 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 自閉症の治療のための化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001575A1 (en) * 2000-05-26 2002-01-03 Foreman David J. Nutritional system for nervous system disorders
US20080112944A1 (en) * 2004-12-01 2008-05-15 Kirkman Group, Inc. Compositions and methods for the treatment of autism
WO2010002972A1 (en) * 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
WO2010120781A1 (en) * 2009-04-13 2010-10-21 Curemark Llc Enzyme delivery systems and methods of preparations and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ferrone, M et al (2007) Pancreatic Enzyme Pharmacotherapy. Pharmacotherapy. Volume 27. Pages 910-920 *

Also Published As

Publication number Publication date
GB201411821D0 (en) 2014-08-13
NZ734194A (en) 2021-02-26
AU2017232048A1 (en) 2017-10-12
MX2019002669A (es) 2019-05-30
GB2511713A (en) 2014-09-10
AU2017232048B2 (en) 2019-05-02
IL233372B (en) 2019-09-26
MX363096B (es) 2019-03-08
IL233372A0 (en) 2014-08-31
MX2014008156A (es) 2015-04-13
HK1257360A1 (zh) 2019-10-18
US20210162024A1 (en) 2021-06-03
RU2654230C2 (ru) 2018-05-17
JP2015503586A (ja) 2015-02-02
KR20200113029A (ko) 2020-10-05
EP2800581A4 (en) 2015-08-12
WO2013103746A1 (en) 2013-07-11
NZ716627A (en) 2017-08-25
US20130224172A1 (en) 2013-08-29
HK1201731A1 (en) 2015-09-11
EP2800581B1 (en) 2024-05-22
CN104144698A (zh) 2014-11-12
NZ737957A (en) 2021-07-30
RU2014130165A (ru) 2016-02-27
JP6810724B2 (ja) 2021-01-06
US20260069667A1 (en) 2026-03-12
DK2800581T3 (da) 2024-06-17
CA2862403C (en) 2022-08-09
JP2019006788A (ja) 2019-01-17
EP2800581A1 (en) 2014-11-12
BR112014016557A8 (pt) 2017-07-04
CA2862403A1 (en) 2013-07-11
JP2021001222A (ja) 2021-01-07
KR20140107665A (ko) 2014-09-04
AU2013206890A1 (en) 2014-07-24
BR112014016557A2 (pt) 2017-06-13
JP6796372B2 (ja) 2020-12-09
KR102315761B1 (ko) 2021-10-20
GB2511713B (en) 2020-03-04
KR20190109564A (ko) 2019-09-25
CN108578684A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
US20260069667A1 (en) Methods of treating behavioral symptoms of neurological and mental disorders
NZ738140A (en) Door closure
US11419821B2 (en) Enzyme delivery systems and methods of preparation and use
US11016104B2 (en) Methods and compositions for the treatment of symptoms of neurological and mental health disorders
NZ738140B2 (en) Tau-binding antibodies
NZ734194B2 (en) Methods of treating behavioral symptoms of neurological and mental disorders
AU2015215910B2 (en) Enzyme delivery systems and methods of preparations and use
AU2013224726B2 (en) Enzyme delivery systems and methods of preparations and use
AU2016202521A1 (en) Enzyme delivery systems and methods of preparations and use
HK1166235B (en) Enzyme delivery systems and methods of preparations and use
HK1166235A (en) Enzyme delivery systems and methods of preparations and use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)